I agree but maybe there is some argument to be made about being able to make cross domain associations.

My speculation is they wanted to cast a wide net to increase the odds of profit. I think that'll turn out to be the wrong approach, but maybe it had to be that way for technical advancement. I think special purpose refinement will end up being the gold mine. Healthcare, drug creation, etc.

Easier to market maybe. I expect them to be single-faced though in the future. The models also get synergistic benefits from learning multiple domains instead of one.